CDKN2A and breast carcinoma: In the phase II clinical study PALOMA-1, it was found that patient selection based on CCDN1 amplification and/or P16 loss (CDKN2A deletion) did not improve outcomes of the administration of palbociclib plus letrozole in HR-positive breast cancer patients [38].